Clinical trials: Diabetes Type I
Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset)
R-5280 in Newly Diagnosed Patients With Type 1 Diabetes
Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
- Conditions
- Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
- Trial name
- R-5280 (NCT06057454)
- Testing
- R-5280
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Rise Therapeutics LLC
Diabetes Mellitus, Type 2
A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects
This is a randomized, double blind, placebo controlled, single ascending dose study to assess the safety, tolerability, PK, PD and IE with metformin following a single oral dose of DA-1241 in healthy male subjects.
- Trial name
- NCT03061981
- Testing
- Metformin, DA-1241
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes Mellitus
A Study Conducted Over 3 Periods to Look at the Drug in the Body
A study conducted over 3 periods to look at the drug in the body.
- Trial name
- NCT01225939
- Testing
- AZD8329
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03170544
- Testing
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Insulin Hypoglycemia, Type 1 Diabetes Mellitus
G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
This is a non-inferiority, multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus.
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Trial name
- NCT03439072
- Testing
- G-Pen, Lilly Glucagon
- Where
- 6 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Xeris Pharmaceuticals
Male Subjects With Type II Diabetes (T2DM)
Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)
This study will be a phase I, first time in human (FiH), randomized, single-blind, placebo-controlled, SAD study in male patients with T2DM, performed at a single study center.
- Trial name
- NCT02935712
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Study for Patients With Type 1 Diabetes
Comparison of blood glucose levels in patients with Type 1 diabetes when they take a new basal insulin analog and when they take insulin glargine
- Trial name
- NCT01049412
- Testing
- LY2605541, Insulin glargine
- Where
- 13 sites in United States, Israel
- Volunteers
- 138 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
This study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014, a new blood sugar lowering insulin, and its effect on blood sugar levels when it is delivered via an…
- Trial name
- NCT03056456
- Testing
- LY900014, Insulin Lispro (Humalog)
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Subcutaneous Administration of Otelixizumab to T1DM Patients
This study will assess the subcutaneous administration of otelixizumab to T1DM patients. The study will provide safety, tolerability, pharmacodynamic and pharmacokinetic information which will enable the identification of…
- Trial name
- RAO112438 (NCT00946257)
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitis
Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State
This trial intends to investigate the pharmacodynamics, pharmacokinetics, safety, and tolerability of insulin GZR33 (hereafter referred to as GZR33) and estimate its potency in comparison with insulin degludec.
- Trial name
- NCT07242664
- Testing
- GZR-33
- Where
- 2 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 1 Diabetes
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group".
- Trial name
- STAR3 (NCT00417989)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 30 sites in United States, Canada
- Volunteers
- 485 people
- Sponsor
- Medtronic MiniMed, Inc.
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
The objective of the trial is to demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus (T1DM) with insulin-induced hypoglycemia.
- Trial name
- NCT03378635
- Testing
- Dasiglucagon, GlucaGen
- Where
- 5 sites in United States, Austria and 2 more
- Volunteers
- 170 people
- Sponsor
- Zealand Pharma
Diabetes Mellitus Type 1
Comparison of the Management of Post-prandial Hyperglycemia by Multiple Bolus Calculators
This prospective, non-randomized, non-controlled, interventional study will determine whether the Roche automated bolus caclulator (ABC) reduces post-meal hyperglycemia better than the competitor's ABC without causing significant…
- Trial name
- NCT01050868
- Testing
- Accu-Chek Combo Kit mg DE/de
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with…
- Trial name
- LuCa-MERIT-1 (NCT05142189)
- Testing
- BNT116, Cemiplimab, Docetaxel
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 320 people
- Sponsor
- BioNTech SE
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System
The purpose of this study is to evaluate the safety and effectiveness of the next-generation DexCom SEVEN Continuous Glucose Monitoring System (SEVEN.2 System) when worn for up to 7-days by subjects >18 years-old with diabetes…
- Trial name
- NCT00722241
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- DexCom, Inc.
Diabetes Mellitus, Type 1
The PSIQS Study - User Experience With Pro-Set
Open label, randomized 2-period cross-over study comparing two continuous subcutaneous insulin infusion sets ; MiniMed® Pro-set® with BD FlowSmart™ technology and MiniMed® Quick-set®
- Trial name
- NCT03242005
- Testing
- MiniMed® Pro-set®, MiniMed® Quick-set®
- Sponsor
- Becton, Dickinson and Company
Type 1 Diabetes, Insulin Pump Users
Feasibility Study of the Solo™ Insulin Pump
The purpose of this study is to assess the safety and usability of the Solo™ insulin MicroPump in subjects with type 1 diabetes who are pump users.
- Trial name
- NCT01055951
- Testing
- Solo MicroPump
- Where
- 3 sites in Austria, Israel
- Volunteers
- 90 people
- Sponsor
- Medingo Ltd
Diabetes Mellitus, Type 1
Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System
This interventional device study aims to compare mainly standard Multiple Daily Injection (MDI) therapy vs. Accu-Chek® Solo Micropump System and investigates participant satisfaction.
- Trial name
- PRO Solo (NCT03478969)
- Testing
- Accu-Chek® Solo micropump system, mylife™ OmniPod® Insulin Management System, Multiple Daily Injections (MDI) therapy
- Where
- 21 sites in Austria, Germany and 2 more
- Volunteers
- 181 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 1
Effect of NN5401 in Japanese Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of this clinical trial is to investigate the blood sugar lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in Japanese subjects with type 1 diabetes.
- Trial name
- NCT01051102
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes
The purpose of this study was to compare the pharmacokinetic (PK) response after inhaled insulin administration with 3 different inhalation regimens and with subcutaneous insulin administration.
- Trial name
- Samba-01 (NCT02713841)
- Testing
- inhaled human insulin (INH), sc insulin lispro (LIS)
- Volunteers
- 12 people
- Sponsor
- Dance Biopharm Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.